A detailed history of Sp Asset Management transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Sp Asset Management holds 7,173 shares of BMY stock, worth $417,683. This represents 0.07% of its overall portfolio holdings.

Number of Shares
7,173
Previous 7,121 0.73%
Holding current value
$417,683
Previous $548,000 6.93%
% of portfolio
0.07%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 08, 2022

BUY
$0.13 - $76.84 $6 - $3,995
52 Added 0.73%
7,173 $510,000
Q2 2022

Aug 03, 2022

BUY
$72.62 - $79.98 $3,631 - $3,999
50 Added 0.71%
7,121 $548,000
Q1 2022

May 09, 2022

SELL
$61.48 - $73.72 $11,927 - $14,301
-194 Reduced 2.67%
7,071 $516,000
Q4 2021

Feb 02, 2022

BUY
$53.63 - $62.52 $6,060 - $7,064
113 Added 1.58%
7,265 $474,000
Q3 2021

Oct 28, 2021

SELL
$59.17 - $69.31 $151,061 - $176,948
-2,553 Reduced 26.31%
7,152 $404,000
Q2 2021

Jul 28, 2021

BUY
$61.91 - $67.42 $123 - $134
2 Added 0.02%
9,705 $655,000
Q1 2021

May 05, 2021

BUY
$59.34 - $66.74 $4,153 - $4,671
70 Added 0.73%
9,703 $620,000
Q4 2020

Feb 08, 2021

SELL
$57.74 - $65.43 $7,044 - $7,982
-122 Reduced 1.25%
9,633 $587,000
Q3 2020

Nov 06, 2020

SELL
$57.43 - $63.64 $418,377 - $463,617
-7,285 Reduced 42.75%
9,755 $622,000
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $394,594 - $461,319
7,198 Added 73.14%
17,040 $592,000
Q1 2020

May 13, 2020

SELL
$46.4 - $67.43 $24,916 - $36,209
-537 Reduced 5.17%
9,842 $549,000
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $510,750 - $666,228
10,379 New
10,379 $666,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Sp Asset Management Portfolio

Follow Sp Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sp Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Sp Asset Management with notifications on news.